Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective—: To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) trial evaluated the effects of fenofibric acid (FA) treatment on cIMT in patients with mixed dyslipidemia on atorvastatin. Approach and Results—: This multicenter, double-blind, placebo-controlled study was performed in patients with mixed dyslipidemia (fasting triglycerides, ≥150 mg/dL; high-density lipoprotein cholesterol, ≤45 [men] or 55 mg/dL [women]; low-density lipoprotein cholesterol, ≤100 mg/dL once and averaging ≤105 mg/dL) and a history of coronary heart disease or risk equivalent. Patients on background atorvastatin (continued on starting dose or titrated to 40 mg, if needed) were randomized to FA 135 mg or placebo. The primary end point was rate of change from baseline through week 104 of the mean posterior-wall cIMT, measured by ultrasound. In patients with controlled low-density lipoprotein cholesterol while on atorvastatin background therapy, rate of change in posterior-wall cIMT was similar with FA plus atorvastatin (−0.006 mm/y) versus atorvastatin monotherapy (0.000 mm/y; P =0.22). FA plus atorvastatin was favored ( P <0.05) in 5 of 24 prespecified subgroups: age ≥60 years, history of coronary artery disease, cIMT >0.795 mm, triglycerides 170 to 235 mg/dL, and statin use at entry. Adverse events were consistent with the known safety profiles of both drugs; however, FA plus atorvastatin was associated with a greater incidence of renal-related adverse events compared with atorvastatin monotherapy (6.5% versus 0.9%). Conclusions—: Compared with atorvastatin monotherapy, FA plus atorvastatin did not further decrease cIMT progression in high-risk patients with mixed dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. (2007) · Circulation · doi:10.1161/circulationaha.106.628875 · Cited by 2,977
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 3×
“There is evidence from other fenofibrate trials that suggest that, once therapy is stopped, creatinine returns to baseline,(22) and long term, there seems to be a reduction in proteinuria.(4) Aggressive hydration after discontinuing treatment may facilitate resolution of renal abnormalities.”
BackgroundCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Den Ruijter, H. M., Peters, S. A. E., Anderson, T. J., Britton, A. R., Dekker, J. M., Eijkemans, M. J., Engström, G., Evans, G. W., de Graaf, J., Grobbee, D. E., et al. (2012) · JAMA · doi:10.1001/jama.2012.9630 · Cited by 760
Lorenz, M. W., Polak, J. F., Kavousi, M., Mathiesen, E. B., Völzke, H., Tuomainen, T.-P., Sander, D., Plichart, M., Catapano, A. L., Robertson, C. M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60441-3 · Cited by 598 · cited 1×
“cIMT has been shown to correlate with risk of future cardiovascular events,(11,12) and changes in cIMT over time have been used extensively to evaluate the potential clinical efficacy of antiatherosclerotic agents.(11,13) Statins, which are well-established agents for reducing the risk of cardiovascular disease events…”
BackgroundScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Self-citationMychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1811 · Cited by 149
Cited by
Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., Liao, X., Lonn, E., Gerstein, H. C., Yusuf, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046361 · Cited by 452
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142
Metadata
- Authors
- Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., Lele, A., & Stolzenbach, J. C.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2014-06
- Volume
- 34
- Issue
- 6
- Pages
- 1298-1306
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2163096122
- Cited by
- 64
- References
- 12
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST). https://app.cochat.ai/papers/10.1161/atvbaha.113.302926
- The paper
- Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., Lele, A., & Stolzenbach, J. C. (2014). Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST). Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.113.302926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.